Clinical Trial News

A clinical trial conducted by the University of Minnesota found that hydroxychloroquine, taken once or twice weekly, does not effectively prevent COVID-19 in health care workers at high risk of exposure, compared to a placebo. The study involved 1,483 participants from the U.S. and Canada, with no statistically significant difference in COVID-19 development between those taking hydroxychloroquine and those on placebo.

Iterum Therapeutics plc announced two data presentations at IDWeek™ 2020, showcasing results from SURE-1 and SURE-2 trials on sulopenem's efficacy in treating uUTI and cUTI. Sulopenem demonstrated superiority over ciprofloxacin in uUTI caused by quinolone non-susceptible pathogens. The company focuses on developing antibiotics against multi-drug resistant pathogens.

LRRC15-targeted antibody-drug conjugates (ADCs) show promise in treating osteosarcoma (OS), with LRRC15-PNU demonstrating superior efficacy over LRRC15-MMAE in inhibiting OS growth in vitro and in vivo. LRRC15 expression, regulated by TGFβ, offers a therapeutic target, especially for high-expressing OS cells, suggesting potential for sensitizing low-expressing cells to ADC treatment.

FDA approved Gilead Sciences' remdesivir as the first fully approved treatment for COVID-19, despite WHO findings of minimal impact on mortality. Gilead faced criticism for high pricing and profit motives. Japan also approved remdesivir, highlighting global efforts to combat the pandemic with antiviral treatments.

Network meta-analysis of PARP inhibitor regimens in BRCA-mutated ovarian cancer showed no significant differences in efficacy and toxicity between upfront and relapsed settings. ASCO value framework indicated similar clinical benefits and net health benefit, with upfront regimens having lower toxicity. Adding bevacizumab to olaparib increased cost per unit net health benefit.

The FDA has approved a new first-line treatment for metastatic or recurrent head and neck cancer, using the immunotherapy drug pembrolizumab, either alone or with chemotherapy. This treatment, developed through research led by Yale's Dr. Barbara A. Burtness, significantly improves survival rates and is less toxic than previous treatments.

The APT Webstudy aims to remotely enroll individuals into a longitudinal study for Alzheimer's research, using online registries and emails for recruitment. As of April 2020, 30,650 participants, predominantly female, highly educated, and Caucasian, were enrolled, with most referrals coming from online registries.

Nivolumab and low-dose ipilimumab show durable clinical benefit for MSI-H/dMMR metastatic CRC patients, with 74% PFS and 79% OS rates at 24 months. The combination, effective in first-line and previously treated patients, is well-tolerated, offering a new treatment option.

Izotropic Corporation has taken a significant step towards market approval for its Breast CT Imaging System by filing a Pre-Submission Application with the U.S. FDA. This move marks a pivotal moment in the company's journey to revolutionize breast cancer imaging, aiming to provide a less painful and more efficient diagnostic tool compared to traditional mammography.

A recent study compared the effectiveness of an ultrasound-guided lung recruitment manoeuvre with a conventional method in reducing postoperative atelectasis in children. The findings suggest that the ultrasound-guided approach may offer better outcomes in preventing intra-operative atelectasis and postoperative desaturation, though its impact on postoperative atelectasis remains uncertain.